Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Novo Nordisk (Present Leader - Semaglutide Portfolio) CagriSema Mechanism: GLP-1 + Amylin agonist Stage: Phase 3 Expected filing: 2026 Weight loss: ~22-23% in trials Amycretin Mechanism: GLP-1 + Amylin Route: injectable + oral research Stage: Phase 2 Next-gen Oral GLP-1 programs Partnership with biotech firms to develop new oral obesity drugs 2
Net margins contract to around 15% due to lower volumes and pricing pressure, causing EPS to flatten or fall to $1.6 or less
Tesamorelin Best non-GLP-1 peptide for moderate weight loss Pros Suitable as an off-label prescription for moderate weight loss Shown in studies to decrease abdominal fat and waist circumference Also shown to increase muscle area and strength Cons Limited studies on non-HIV populations Elevated cancer risk for certain groups Not ideal for rapid weight loss Usually requires 5-7 injections per week Tesamorelin is an off-label prescription for weight loss
Prioritize stress management techniques and regular physical activity during daytime hours
Don't ignore hydration
Wegovy may cause various side effects ranging from mild to severe
US$ 20.39
US$ 26.88
US$ 21.81
US$ 29.04
